✨ Free AI Report
Opthea Limited: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Opthea Limited
Company Research

Opthea Limited: Business Overview, Financials & Competitive Analysis

Opthea is a clinical-stage biopharmaceutical company developing drugs for eye diseases, with its lead product sozinibercept (OPT-302) in Phase 3 trials designed to inhibit VEGF-C and VEGF-D to treat wet age-related ma...

Analyst-debate audio for Opthea Limited

AskCyborg analysts argue the bull and bear cases for Opthea Limited across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
2/ 10Challenged

Cyborg Score thesis

High-risk turnaround story requiring successful strategic pivoting to survive; significant downside risk with limited near-term...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - Ophthalmology/Retinal Diseases
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Opthea Limited Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Opthea Limited Overview

Pro stress-test →

Opthea is a clinical-stage biopharmaceutical company developing drugs for eye diseases, with its lead product sozinibercept (OPT-302) in Phase 3 trials designed to inhibit VEGF-C and VEGF-D to treat wet age-related macular degeneration and diabetic macular edema. The company targets a large patient population in a therapeutic area with significant unmet medical needs.

Strategic Profile

Pro stress-test →

The company recently experienced a significant setback when its Phase 3 COAST and ShORe trials for sozinibercept failed to meet primary endpoints, leading to major restructuring including management changes, 80%+ workforce reduction, a settlement with DFA Investors via USD20M payment and 9.99% equity issuance, leaving approximately USD20M in cash. Opthea now faces strategic uncertainty with new leadership and a planned six-month strategic review.

Competitive Landscape

Pro stress-test →

Opthea competes in the wet AMD and DME treatment space dominated by established players administering anti-VEGF-A therapies. Wet AMD affects approximately 3.5 million people in the US and Europe, with many patients not achieving optimal vision outcomes with current anti-VEGF-A therapies. However, Opthea's failed Phase 3 trials have significantly weakened its competitive position.

Industry Context

Opthea Limited operates in Biopharmaceuticals - Ophthalmology/Retinal Diseases.

Key facts

Founded: 2015 · Headquarters: Melbourne, Australia · Employees: Significantly reduced post-restructuring · Revenue: $0.146M (2025) · Market cap: $0.82B AUD

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Opthea Limited.

  • Phase 3 COAST and ShORe trials failed primary endpoints for sozinibercept in wet AMD, representing a major clinical setback after years of development investment
  • Company underwent drastic restructuring with 80%+ workforce reduction and significant management departures in September 2025
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • September 2025Major management and workforce restructuring; CEO Dr Fred Guerard, CFO Tom Reilly departed; Dr Jeremy Levin assumed CEO responsibilities
  • 2025COAST and ShORe Phase 3 trials failed to meet primary endpoints for sozinibercept in wet AMD
  • +1 moreTrack every material event for Opthea Limited as it happens. Explore monitoring →
Get alerted when Opthea Limited has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Anti-VEGF-A TherapiesStandard-of-care treatments dominating wet AMD market→Other VEGF Pathway InhibitorsCompeting approaches to retinal disease treatment→

Compare Opthea Limited with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Opthea Limited operates in Biopharmaceuticals - Ophthalmology/Retinal Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - Ophthalmology/Retinal Diseases research →
NEW · MCP server

Ask your AI assistant about Opthea Limited

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Opthea Limited and its top competitor on Cyborg Score”
“What did Opthea Limited do this quarter?”
“Is Opthea Limited a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Opthea Limited do?+
Opthea is a clinical-stage biopharmaceutical company developing drugs for eye diseases, with its lead product sozinibercept (OPT-302) in Phase 3 trials designed to inhibit VEGF-C and VEGF-D to treat wet age-related ma...
What is Opthea Limited's Cyborg Score?+
Opthea Limited has a Cyborg Score of 2/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Opthea Limited's main competitors?+
Named competitors include Anti-VEGF-A Therapies, Other VEGF Pathway Inhibitors. The full competitive landscape is in the AskCyborg report.
How can I get the full Opthea Limited research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Opthea Limited research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Opthea Limited over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceuticals - Ophthalmology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Belite Bio, Inc5Kodiak Sciences Inc.3KALA BIO, Inc.